Candidate drugs against SARS-CoV-2 and COVID-19

Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.

• Tipo de recurso: Article of journal
• Fecha de publicación: 2020
• Institución: Universidad de Bogotá Jorge Tadeo Lozano
• Repositorio: Expeditio: repositorio UTadeo
• Idioma: eng
• OAI Identifier: oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12169
• Acceso en línea: https://www.sciencedirect.com/science/article/pii/S1043661820311671?via%3Dihub; http://hdl.handle.net/20.500.12010/12169; https://doi.org/10.1016/j.phrs.2020.104859
• Palabra clave: COVID-19; Síndrome respiratorio agudo grave; COVID-19; SARS-CoV-2; Coronavirus; Drugs; Camostat; Chloroquine; Remdesivir; Lopinavir; Ritonavir; Favipiravir; Arbidol; Phytochemicals
• License: Acceso restringido